Percutaneous transluminal renal sympathetic denervation for resistant hypertension
Closed for comments This consultation ended on at Request commenting lead permission
3 Committee considerations
The evidence
3.1 NICE did a rapid review of the published literature on the efficacy and safety of this procedure. This comprised a comprehensive literature search and detailed review of the evidence from 9 sources, which was discussed by the committee. The evidence included 1 Cochrane review, 1 meta-analysis, 2 randomised controlled trials, 1 3‑arm randomised trial and 4 case series (registries). It is presented in the summary of key evidence section in the interventional procedures overview.
3.2 The professional experts and the committee considered the key efficacy outcomes to be: reduction in blood pressure, reduction in use of antihypertensive drugs and reduction in end-organ damage.
3.3 The professional experts and the committee considered the key safety outcomes to be: pain and renal artery damage.
3.4 Patient commentary was sought but none was received.
Committee comments
3.5 The committee noted that the technology has evolved and there are different methods of doing this procedure.
3.6 The committee noted that most evidence that the committee reviewed for this procedure is for resistant hypertension. This guidance does not cover using the procedure for other forms of hypertension.
Tom Clutton-Brock
Chair, interventional procedures advisory committee
September 2022
ISBN:
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions